Cellebrite DI (NASDAQ:CLBT) Stock Price Down 6.2% Following Analyst Downgrade

Cellebrite DI Ltd. (NASDAQ:CLBT)’s share price was down 6.2% during trading on Monday after Weiss Ratings downgraded the stock from a hold (c-) rating to a sell (d+) rating. The company traded as low as $10.95 and last traded at $10.45. 428,923 shares traded hands during trading, a decline of 80% from the average daily volume of 2,130,758 shares. The stock had previously closed at $11.14.

CLBT has been the subject of a number of other research reports. JPMorgan Chase & Co. reduced their price objective on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday. DA Davidson lowered their target price on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday. Lake Street Capital cut their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a report on Friday. Finally, Needham & Company LLC reduced their price target on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research report on Friday. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $16.70.

Insider Buying and Selling

In other Cellebrite DI news, CEO Thomas E. Hogan sold 139,713 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $15.39, for a total transaction of $2,150,183.07. Following the completion of the transaction, the chief executive officer directly owned 790,548 shares of the company’s stock, valued at approximately $12,166,533.72. This represents a 15.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO David Barter sold 41,734 shares of the firm’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the sale, the chief financial officer directly owned 334,219 shares of the company’s stock, valued at $5,474,507.22. This represents a 11.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 285,276 shares of company stock worth $4,470,330 in the last ninety days. 5.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its holdings in Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares during the last quarter. Advisory Services Network LLC purchased a new stake in Cellebrite DI during the third quarter valued at about $40,000. CWM LLC lifted its holdings in Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after purchasing an additional 889 shares during the last quarter. First Horizon Corp boosted its position in Cellebrite DI by 421.8% during the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after purchasing an additional 2,337 shares during the period. Finally, Elevation Wealth Partners LLC bought a new position in Cellebrite DI during the second quarter worth about $44,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price Performance

The stock has a market cap of $2.59 billion, a PE ratio of 47.22, a P/E/G ratio of 1.38 and a beta of 1.18. The firm’s 50 day moving average price is $14.47 and its two-hundred day moving average price is $14.01.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.